FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Veterinary pathology2010; 48(1); 254-265; doi: 10.1177/0300985810379434

Cyclooxygenase-2 expression in animal cancers.

Abstract: Cyclooxygenase (COX; also known as prostaglandin endoperoxide synthase) is a key enzyme in the biochemical pathway leading to the synthesis of prostaglandins. A large amount of epidemiological and experimental evidence supports a role for COX-2, the inducible form of the enzyme, in human tumorigenesis, notably in colorectal cancer. COX-2 mediates this role through the production of PGE(2) that acts to inhibit apoptosis, promote cell proliferation, stimulate angiogenesis, and decrease immunity. Similarly, COX-2 is believed to be involved in the oncogenesis of some cancers in domestic animals. Here, the author reviews the current knowledge on COX-2 expression and role in cancers of dogs, cats, and horses. Data indicate that COX-2 upregulation is present in many animal cancers, but there is presently not enough information to clearly define the prognostic significance of COX-2 expression. To date, only few reports document an association between COX-2 expression and survival, notably in canine mammary cancers and osteosarcomas. Some evidence suggests that COX inhibitors could be useful in the prevention and/or treatment of certain cancers in domestic animals, the best example being urinary transitional cell carcinomas in dogs. However, determination of the levels of COX-2 in a tumor does not appear to be a good prognostic factor or a good indicator for the response to nonsteroidal anti-inflammatory drug therapy. Clearly, additional research, including the development of in vitro cell systems, is needed to determine if COX-2 expression can be used as a reliable prognostic factor and as a definite therapeutic target in animal cancers.
Get Full Text
Publication Date: 2010-09-27 PubMed ID: 20876365DOI: 10.1177/0300985810379434Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study examines the role of an enzyme known as COX-2 in tumorigenesis of animals, including dogs, cats, and horses, showing an upregulation in many animal cancers. The study concludes, however, that currently not enough data exists to define the prognostic significance or its potential as a therapeutic target in animal cancer treatment.

Understanding Cyclooxygenase-2 or COX-2

  • Cyclooxygenase, also known as prostaglandin endoperoxide synthase, is an integral enzyme in the production of prostaglandins, which play a significant role in causing inflammation and pain in the body.
  • COX-2 is an inducible form of this enzyme, known to be a key player in human tumorigenesis, especially in colorectal cancer. It promotes the production of PGE(2) that works to inhibit cell death, encourage cell proliferation, stimulate the formation of blood vessels, and suppress immunity.

Role of COX-2 in Animal Cancers

  • Research suggests a similar role of COX-2 in the onset of certain cancers in domestic animals. Evidence indicates that many animal cancers exhibit COX-2 upregulation, meaning an increase in the production level of this enzyme.
  • However, current data is insufficient to explicitly establish the prognostic significance of COX-2 expression in animals. Only a few studies show an association between COX-2 expression and survival, with notable instances in canine mammary cancers and osteosarcomas.

Potential of COX-2 Inhibitors in Animal Cancer Treatment

  • Some evidence indicates that COX inhibitors, which are drugs that can reduce the production of prostaglandins, might prove useful in the prevention or treatment of certain cancers in domestic animals. Urinary transitional cell carcinomas in dogs serve as the best example for this suggestion.
  • However, the research underlines that merely determining the levels of COX-2 in a tumor is not an effective prognostic factor, nor does it reliably indicate the potential response to nonsteroidal anti-inflammatory drug therapy.
  • Therefore, it urges further focused research and the development of in vitro cell systems to definitively determine whether COX-2 expression can be used as a valid prognostic factor and therapeutic target in treating animal cancers.

Cite This Article

APA
Doré M. (2010). Cyclooxygenase-2 expression in animal cancers. Vet Pathol, 48(1), 254-265. https://doi.org/10.1177/0300985810379434

Publication

Veterinary pathology
ISSN: 1544-2217
NlmUniqueID: 0312020
Country: United States
Language: English
Volume: 48
Issue: 1
Pages: 254-265

Researcher Affiliations

Doré, M
  • Département de pathologie et microbiologie, Faculté de médecine vétérinaire, Université de Montréal, 3200 Sicotte, St-Hyacinthe, Québec, Canada. monique.dore@umontreal.ca

MeSH Terms

  • Animals
  • Cyclooxygenase 2 / genetics
  • Cyclooxygenase 2 / metabolism
  • Gene Expression Regulation, Enzymologic / physiology
  • Gene Expression Regulation, Neoplastic / physiology
  • Humans
  • Neoplasms / enzymology
  • Neoplasms / metabolism

Citations

This article has been cited 36 times.
  1. Lu CH, Yu SH, Wu CH, Yeh JL, Chang HW, Jeng CR, Chang YC. Effects of selective cyclooxygenase-2 inhibitor robenacoxib on primary cells derived from feline injection-site sarcoma. J Cell Mol Med 2023 Aug;27(15):2183-2193.
    doi: 10.1111/jcmm.17717pubmed: 37334757google scholar: lookup
  2. Fu DR, Kadosawa T. Comparison of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) immunohistochemical expression and outcomes in canine nasal carcinomas treated with radiation therapy. J Vet Med Sci 2022 Sep 5;84(9):1237-1243.
    doi: 10.1292/jvms.22-0106pubmed: 35851267google scholar: lookup
  3. Maekawa N, Konnai S, Asano Y, Sajiki Y, Deguchi T, Okagawa T, Watari K, Takeuchi H, Takagi S, Hosoya K, Kim S, Ohta H, Kato Y, Suzuki Y, Murata S, Ohashi K. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy. Sci Rep 2022 Jun 3;12(1):9265.
    doi: 10.1038/s41598-022-13484-8pubmed: 35665759google scholar: lookup
  4. Howard J, Fisher J, Tolbert MK. Invasive tracheal neoplasia in eight cats: descriptive cases and review of the current literature. JFMS Open Rep 2017 Jan-Jun;3(1):2055116917690074.
    doi: 10.1177/2055116917690074pubmed: 35145722google scholar: lookup
  5. Vargas Estrada CR, Firmo BF, Belchior Vela D, Maronezi MC, Ramirez Uscategui RA, Gasser B, Rossi Feliciano MA, Pavan L, Nogueira Aires LP, Piovan Lima G, De Nardi AB. Ultrasonographic assessment of renal perfusion in bitches with mammary carcinoma treated with long-term carprofen. Sci Rep 2021 Dec 2;11(1):23277.
    doi: 10.1038/s41598-021-02781-3pubmed: 34857853google scholar: lookup
  6. Gregório H, Magalhães TR, Pires I, Prada J, Carvalho MI, Queiroga FL. The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review. Vet Med Sci 2021 Jul;7(4):1107-1119.
    doi: 10.1002/vms3.460pubmed: 33751829google scholar: lookup
  7. Valdivia G, Alonso-Diez Á, Pérez-Alenza D, Peña L. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review. Front Vet Sci 2021;8:623800.
    doi: 10.3389/fvets.2021.623800pubmed: 33681329google scholar: lookup
  8. Musser ML, Viall AK, Phillips RL, Hostetter JM, Johannes CM. Analysis of gene expression of prostaglandin EP4 receptor in canine osteosarcoma. Can J Vet Res 2021 Jan;85(1):68-71.
    pubmed: 33390656
  9. Musser ML, Viall AK, Phillips RL, Hostetter JM, Johannes CM. Gene expression of prostaglandin EP4 receptor in three canine carcinomas. BMC Vet Res 2020 Jun 22;16(1):213.
    doi: 10.1186/s12917-020-02431-2pubmed: 32571310google scholar: lookup
  10. Szweda M, Rychlik A, Babińska I, Pomianowski A. Cyclooxygenase-2 as a Biomarker with Diagnostic, Therapeutic, Prognostic, and Predictive Relevance in Small Animal Oncology. J Vet Res 2020 Mar;64(1):151-160.
    doi: 10.2478/jvetres-2020-0018pubmed: 32258812google scholar: lookup
  11. Szweda M, Rychlik A, Babińska I, Pomianowski A. Significance of Cyclooxygenase-2 in Oncogenesis. J Vet Res 2019 Jun;63(2):215-224.
    doi: 10.2478/jvetres-2019-0030pubmed: 31276061google scholar: lookup
  12. Grassinger JM, Merz S, Aupperle-Lellbach H, Erhard H, Klopfleisch R. Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas. Vet Sci 2019 Mar 19;6(1).
    doi: 10.3390/vetsci6010031pubmed: 30893857google scholar: lookup
  13. Berger EP, Johannes CM, Jergens AE, Allenspach K, Powers BE, Du Y, Mochel JP, Fox LE, Musser ML. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. J Vet Intern Med 2018 Nov;32(6):2045-2053.
    doi: 10.1111/jvim.15335pubmed: 30307656google scholar: lookup
  14. Carvalho MI, Bianchini R, Fazekas-Singer J, Herrmann I, Flickinger I, Thalhammer JG, Pires I, Jensen-Jarolim E, Queiroga FL. Bidirectional Regulation of COX-2 Expression Between Cancer Cells and Macrophages. Anticancer Res 2018 May;38(5):2811-2817.
    doi: 10.21873/anticanres.12525pubmed: 29715103google scholar: lookup
  15. Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer 2018 Mar 13;18(1):288.
    doi: 10.1186/s12885-018-4156-5pubmed: 29534696google scholar: lookup
  16. Klarich DS, Penprase J, Cintora P, Medrano O, Erwin D, Brasser SM, Hong MY. Effects of moderate alcohol consumption on gene expression related to colonic inflammation and antioxidant enzymes in rats. Alcohol 2017 Jun;61:25-31.
    doi: 10.1016/j.alcohol.2017.02.179pubmed: 28599714google scholar: lookup
  17. Azevedo C, Brawner W, Schleis Lindley S, Smith A. Multimodal non-surgical treatment of a feline tracheal adenocarcinoma. JFMS Open Rep 2017 Jan-Jun;3(1):2055116916689630.
    doi: 10.1177/2055116916689630pubmed: 28491448google scholar: lookup
  18. Carvalho MI, Silva-Carvalho R, Pires I, Prada J, Bianchini R, Jensen-Jarolim E, Queiroga FL. A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs. Biomed Res Int 2016;2016:4917387.
    doi: 10.1155/2016/4917387pubmed: 28053982google scholar: lookup
  19. Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Dauksa A, Paskauskas S, Gulbinas A, Dambrauskas Z. Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy. Langenbecks Arch Surg 2016 Feb;401(1):99-111.
    doi: 10.1007/s00423-015-1364-1pubmed: 26691217google scholar: lookup
  20. Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol 2015 Dec 14;21(46):13004-19.
    doi: 10.3748/wjg.v21.i46.13004pubmed: 26675757google scholar: lookup
  21. Barton MH, Darden JE, Clifton S, Vandenplas M. Effect of firocoxib on cyclooxygenase 2, microsomal prostaglandin E2 synthase 1, and cytosolic phospholipase A2 gene expression in equine mononuclear cells. Am J Vet Res 2015 Dec;76(12):1051-7.
    doi: 10.2460/ajvr.76.12.1051pubmed: 26618729google scholar: lookup
  22. Safra N, Hayward LJ, Aguilar M, Sacks BN, Westropp JL, Mohr FC, Mellersh CS, Bannasch DL. DNA Sequence Variants in the Five Prime Untranslated Region of the Cyclooxygenase-2 Gene Are Commonly Found in Healthy Dogs and Gray Wolves. PLoS One 2015;10(8):e0133127.
    doi: 10.1371/journal.pone.0133127pubmed: 26244515google scholar: lookup
  23. Nakhjavani M, Zarghi A, H Shirazi F. Cytotoxicity of selected novel chalcone derivatives on human breast, lung and hepatic carcinoma cell lines. Iran J Pharm Res 2014 Summer;13(3):953-8.
    pubmed: 25276196
  24. Amorim I, Taulescu MA, Ferreira A, Rêma A, Reis CA, Faustino AM, Cătoi C, Gärtner F. An immunohistochemical study of canine spontaneous gastric polyps. Diagn Pathol 2014 Sep 18;9:166.
    doi: 10.1186/s13000-014-0166-zpubmed: 25230726google scholar: lookup
  25. Ustün Alkan F, Ustüner O, Bakırel T, Cınar S, Erten G, Deniz G. The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal 2012;2012:976740.
    doi: 10.1100/2012/976740pubmed: 23251109google scholar: lookup
  26. Lao HC, Akunda JK, Chun KS, Flake GP, Yuspa SH, Langenbach R. Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation. Carcinogenesis 2012 Nov;33(11):2293-300.
    doi: 10.1093/carcin/bgs267pubmed: 22902545google scholar: lookup
  27. Musser ML, Doke R, Viall AK, Phillips RL, Fasina O, Johannes CM. High expression of prostaglandin EP4 receptor mRNA in feline head and neck squamous cell carcinoma. Can J Vet Res 2025 Jul;89(3):113-119.
    pubmed: 40636001
  28. Diop N, Canonne AM, Huet H, Reyes-Gomez E, Béguin J. Immunohistochemical evaluation of cyclooxygenase-2 expression in feline nasal malignant epithelial tumours. J Feline Med Surg 2025 Jun;27(6):1098612X251314336.
    doi: 10.1177/1098612X251314336pubmed: 40519042google scholar: lookup
  29. Sesanto C, Lawrence J, Holkham J, Serra JC, Bavcar S, Parys M. Long-term outcome following multimodality treatment in a cat with recurrent laryngeal adenocarcinoma. Vet Radiol Ultrasound 2025 Jan;66(1):e13466.
    doi: 10.1111/vru.13466pubmed: 39681987google scholar: lookup
  30. Pauly LAM, Junginger J, Oechtering GU, Hewicker-Trautwein M, Rösch S. Expression of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, cyclooxygenase-2, survivin, E-cadherin and Ki-67 in canine nasal carcinomas and sarcomas - a pilot study. Front Vet Sci 2024;11:1388493.
    doi: 10.3389/fvets.2024.1388493pubmed: 39268521google scholar: lookup
  31. Thapa R, Moglad E, Goyal A, Bhat AA, Almalki WH, Kazmi I, Alzarea SI, Ali H, Oliver BG, MacLoughlin R, Dureja H, Singh SK, Dua K, Gupta G. Deciphering NF-kappaB pathways in smoking-related lung carcinogenesis. EXCLI J 2024;23:991-1017.
    doi: 10.17179/excli2024-7475pubmed: 39253534google scholar: lookup
  32. Garcia APV, Taborda DYO, Reis LA, de Paula AM, Cassali GD. Collagen modifications predictive of lymph node metastasis in dogs with carcinoma in mixed tumours. Front Vet Sci 2024;11:1362693.
    doi: 10.3389/fvets.2024.1362693pubmed: 38511192google scholar: lookup
  33. Pimenta J, Prada J, Pires I, Cotovio M. Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors. Vet Sci 2024 Feb 7;11(2).
    doi: 10.3390/vetsci11020077pubmed: 38393095google scholar: lookup
  34. Repetti CSF, Rueda JR, Porto CD, Franco RP, Girio RJS, Manhoso FFR, da Costa IB. Palliative care for cancer patients in veterinary medicine. Vet Med (Praha) 2023 Jan;68(1):2-10.
    doi: 10.17221/76/2022-VETMEDpubmed: 38384994google scholar: lookup
  35. Rinaldi V, Finotello R, Boari A, Cabibbo E, Crisi PE. Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma. Vet Sci 2023 Nov 22;10(12).
    doi: 10.3390/vetsci10120664pubmed: 38133215google scholar: lookup
  36. Vazquez E, Lipovka Y, Cervantes-Arias A, Garibay-Escobar A, Haby MM, Queiroga FL, Velazquez C. Canine Mammary Cancer: State of the Art and Future Perspectives. Animals (Basel) 2023 Oct 9;13(19).
    doi: 10.3390/ani13193147pubmed: 37835752google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.